Summary A brain tumour-associated marker, urokinase (UK), was investigated using rabbit anti-UK polyclonal and munne anti-UK monoclonal antibodies, which were prepared by immunization with low molecular weight UK (LMW-UK) and high molecular weight urokinase (HMW-UK) synthetic peptide respectively. The polyclonal antibody cross-reacted with both LMW-UK and HMW-UK. whereas the murne MAbs were specific for HMW-UK. These immunological probes were used to study urokinase in glioma extracts, tissues, sera and cell lines that had been prepared from prmary cultures of freshly dissected gliomas. Radioimmunoassays showed that glioma extracts had much higher level (5-to 44-fold) of UK than normal human brain extracts. This result was confirmed by immunoblotting of electrophoresis gels of glioma and human brain extracts. Immunohistochemical study using anti-UK MAb demonstrated much higher levels of UK in glioma tissue than normal brain tissue. Immunohistochemical study using anti-UK MAbs localized UK on the cell surface of glioma cells. Anti-UK MAbs inhibited the proliferation of AA cell lines and GB cell lines (500c to > 90%) and exerted minor effects (< 20%) on normal human liver, intestine and lymphocyte cell lines. Taken together, these results suggest that anti-UK MAbs may have therapeutic potential for human gliomas and cancer metastasis.
Considerable indirect ex idence from model tumour svstems has accumulated to show that invasion and metastasis in solid tumours require the action of tumour-associated proteases that promote the dissolution of the surrounding tumour matrix and the basement membranes. Receptor-bound urokinase-txpe plasminogen actixvator (uPA) appears to play a key role in these ex ents (Dano et al. 1986 : Duffx. 1987 and Zucker. 1988 .
Plasminogen actix ator is a serine protease existing in two forms known as tissue type (tPA) and urokinase tx-pe (uPA) (Sobel et al. 1952 : Giinzler et al. 1982a .b: Nielsen et al. 1982 : Wun et al. 1982 : Salerno et al. 1984 : Riccio et al. 1985 . uPA converts plasminogen into plasmin and thus mediates pericellular proteolysis during cell migration and tissue remodelling, under phy siological and pathophy siological conditions (Gnrmann et al. 1976 : Gerdin and Saldeen. 1978 : Plow et al. 1982 : Salo et al. 1982 : W'ainber! et al. 1982 : Booth et al. 1983 and NC, and Kellen. 1983 August 1997 Correspondence to M-SI Abaza membrane. Hence. receptor-bound uPA v ill promote plasminogen actixation and thus the dissolution of the tumour matrix and the basement membrane. which is a prerequisite for invasion and metastasis.
Plasminogen actix ators in tumours of the central nernous sx stem hax e not been studied extensix ely despite the intense in estigation into their possible role in cancer biologv Hoosein et al. 1991 : Foekens et al. 1992 : Hollas et al. 1992 : Kobaxashi et al. 1992 Reith and Rucklidge et al. 1992 : Sumivoshi et al. 1992 : Hsui et al. 1993 : Janicke et al. 1993 : Pujade-Lauraine et al. 1993 : Yamashita et al. 1993 : Achbarou et al. 1994 : Bianchi et al. 1994 : Bouchet et al. 1994 and Young et al. 1994 . In this study. we report the oxverexpression of urokinasetype plasminogen activator in -liomas. its localization on human glioma cell surface and the antitumorigenic effect of anti-UK MAbs against human malignant brain tumour cell lines.
MATERIALS AND METHODS Materials
Brain tumour extracts were prepared from wet tissue samples (2 g) homocenized by biohomogenizer (Fisher Scientific) in 10 mxis phosphate-buffered saline (PBS) buffer (pH 7.2) at 4 C wxith 100 nvm phenylmethylsulphonxl fluoride (PPMSF) as protease inhibitor. After centrifugation ( 17 000 r.p.m. 90 min at 4-C) of the samples. protein concentrations in the supematants w-ere determined.
Frozen sections (about 5 zm in thickness)w(ere prepared and fixed in 95%7c ethanol and stored at -70 C or processed directly. Cell lines (Cl -Cl,) were prepared from freshly removed tumours of glioma patients. Anti-UK MAbs were prepared by immunization with high molecular weight urokinase synthetic peptides. They showed exquisite specificity to UK and their binding was blocked by using an excess of the immunogen (this will be described in a separate publication), whereas rabbit anti-UK polyclonal antibody was prepared by immunization with LMW-UK.
METHODS
Binding studies 
PH]Thymidine uptake by glioma cell lines
[ H]Thymidine uptake was used to monitor the proliferation of three glioma cell lines (one anaplastic astrocvtoma. AA. tw o glioblastoma multiforme. GB1 and GB2). In this experiment various cell numbers (in triplicate) of each cell line were incubated with a fixed amount of [ Hlthymidine (2 jCi per well) for 18 h at 37°C in a humidified 5% carbon dioxide atmosphere. The cells were then harvested, washed (lOx) with distilled water and the amount of radioactivity on the filter was measured using a beta counter.
Effect of radiation (10 Gy mim1) on glioma cell line prolifertion For our study. the negative control for glioma cell lines was prepared by irradiation using caesium-137 gamma radiaton from a Gammacell 1000. In this experiment. a fixed number of glioma cell lines (50 1l per well of 5 x I0W cells ml-'). which gave a strong 
RESULTS
Binding of anti-UK antibodies to malignant glioma and normal brain exbtacts Equal concentrations of malignant glioma and normal brain extracts were analysed for their content of urokinase using anti-UK MAb4 and rabbit anti-LMW-UK. Glioma extracts contained a much higher (5-to 44-fold) amount of UK than normal human brain extracts ( Figure IA ). This result is confuimed by analysing extracts of four other malignant glioblastomas ( Figures IB and C: 1-4) . four malignant anaplastic astrocytomas and three glioma cell line supernatants ( Figure IB and C: Cl -C) using anti-UK MAb4 ( Figure IB) Immunofluorescence study on human glioma frozen sections and cells
The aim of the immunofluorescence experiments was to examine the levels of UK in nine frozen sections of human malignant glioma and normal brain tissues to confirm the results of RIA and immunoblotting. Frozen sections of human malignant glioma ( Figure 2A ) and normal human brain ( Figure 2B ) were immunofluorescent stained for UK using anti-UK MAb4. The rlioma tissue exhibited very striking immunofluorescence staining compared with human brain. which gave much less staining for UK. These data confirmed the results of RIAs (Figure 1 .) To use anti-UK MAbs for glioma therapy. a prerequisite of recognition of glioma cell surface should be met. The ability of anti-UK MAb to bind to glioma cell surface was investigated by indirect immunofluorescence. Figure 2C gave very clear evidence for the localization of uPA on the surfaces of glioma cells that showed no fluorescence when treated with unrelated antibody ( Figure 2D ) as a negative control for anti-UK MAb. Staining of nuclei or any other cell organelles was excluded because the cell membrane is impermeable to antibody. and when glioma cells were prepared for surface staining they were fixed with paraformaldehyde but did not permeabilize. so anti-UK mAbs would not be able to translocate the cell membrane.
Immunoblotting of malignant glioma and human brain Figure 4 and Table 1. show-ed that MAb UK4 inhibited the proliferation of the AA cell line (97%). the GBl cell line (88.9%7). the GB2 cell line (99.35%7). liver cell line (20%7c). intestine cell line (16.6%) and lymphocyte cell line (18%7c) at a concentration 8 x l0-1"MN ( Figure 4A ). MAbAB3 inhibited the proliferation of the AA cell (60%7). the GBI cell line (77%). the GB2 cell line (68%7). the lixer cell line (18%). the intestine cell line (17%c) and lymphocyte ceHl line (17.35%7c) at a concentration 0.495 x 10-1) m ( Figure 4B ). MAb5 inhibited the proliferation of the AA cell line (84.33%). the GBI cell line (70.19'i . the GB2 cell line (88.75%7r) . the lixer cell line (no inhibition). the intestine cell line (8.5%) and lymphocyte cell line (18%7) at a concentration 1.63 x 10-1m ( Figure 4C ). MAb D4A8 inhibited the proliferation of the AA cell line (52%7c). the GB1 cell line (70%7c). the GB2 cell line (60%). the lixer cell line (19%7) . the intestine cell line (5%7) and the lymphocyte cell line (18%7) at a concentration 0.665 x 10 NI ( Figure 4D ). Normal mouse IgM or IgG had an average inhibitory effect of < 10%7c on gliomas and normal human lines (Figure 4 : Strickland. 1980 ). In the present studx glioma tissue showed a xern large increase (5 to 44-fold) in UK lex els in alioma tissues compared wxith normal human brain tissues (Figures 1-3 ). Enhanced production of plasminogen actix ator has also generally been associated w-ith some cellular responses to tumour promoters (Wigler and Weinstein. 1976) . retinoids (Wilson and Reich. 1978) and DNA damagge (Miskin and Reich. 1980 
